Damage to small blood vessels of the eye appears to be a significant marker for an increased risk of stroke in patients with diabetes, suggesting that the microvascular pathology inherent to diabetic retinopathy may have greater cardiovascular implications, according to a study presented at the American Stroke Association’s (ASA) International Stroke Conference (ISC) 2020 in Los Angeles, US.
In a dinner symposium organised by Boehringer Ingelheim Malaysia, Dr Alice Cheng spoke on how cardiovascular outcome trials (CVOTs) have evolved and impacted the use of antihyperglycaemic agents such as sodium-glucosecotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in clinical practice.
The use of fish oil and its components may yield favourable effects on psoriasis and its comorbidities, namely obesity, cardiovascular disease and metabolic disease, when combined with conventional treatments, as reported in a recent study.
Gestational exposure to perfluoroalkyl substances (PFAS) negatively correlates with birth size and increased thyroid hormone (TH) concentrations, but such association does not explain why some children exposed to PFAS have lower weight, suggests a study.
Use of pioglitazone is associated with reduced risks of all-cause mortality and noncardiovascular (non-CV) death among patients with type 2 diabetes mellitus (T2DM) who are undergoing insulin therapy, a recent study has shown.
Pregnancy, coupled with a history of infertility, is associated with a higher risk of diabetes but not coronary artery calcification (CAC) among glucose-intolerant premenopausal women, a study reveals.
There is a high prevalence of metabolic syndrome (MetS) in patients with psoriasis in Singapore, which is nearly threefold higher than the general population, results of a cross-sectional study have shown.
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.